原料药产业高质量发展

Search documents
中国原料药行业发展现状及趋势预测(2025)
Sou Hu Cai Jing· 2025-07-10 09:52
Industry Overview - The Chinese active pharmaceutical ingredients (API) industry plays a crucial role in the pharmaceutical sector, being the largest producer and exporter globally, particularly in antibiotics, vitamins, and analgesics [8][31] - APIs are essential for drug production, requiring processing into formulations for clinical use, and are widely applied in pharmaceuticals, cosmetics, and other fields [8][10] Market Development - The global API market is steadily growing, projected to reach $226.1 billion in 2024, with China's chemical API revenue expected to be ¥578.3 billion, accounting for 35.5% of the global market [3][39] - The biopharmaceutical API market in China was approximately ¥120 billion in 2023, anticipated to grow to ¥180 billion by 2025, reflecting a compound annual growth rate of about 12% [3][39] - In terms of capacity, China's API production peaked at 3.48 million tons in 2017 but declined due to environmental regulations, with a gradual recovery starting in 2020 [3][40] Enterprise Landscape - By 2024, three companies are expected to exceed ¥10 billion in revenue, with New and Better being the leader, while the majority of enterprises are concentrated in Jiangsu and Shandong provinces [4][39] - The market is characterized by a low concentration, with small and medium-sized enterprises dominating, and direct sales being the primary sales model [4][39] Challenges Faced - The industry faces several challenges, including insufficient investment in R&D, high market entry barriers, lack of industry chain collaboration, intensified competition, and increased compliance costs [4][39] - Domestic regulatory issues include a dual-track system and inadequate transport adaptability, which complicate operations [4][39] Future Trends and Opportunities - The growth in pharmaceutical demand, advancements in biotechnology, and supportive policies present significant opportunities for the industry [4][39] - Key trends include the expiration of patents leading to market expansion, environmental regulations driving industry consolidation, integration of APIs and formulations, and the development of Contract Development and Manufacturing Organizations (CDMO) [4][39] - The industry is encouraged to embrace green practices, increase innovation investments, and enhance industry collaboration to improve competitiveness [4][39]